File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Effects of gliclazide and glibenclamide on platetet function, fibrinolysis and metabolic control in diabetic patients with retinopathy | EFFETS DU GLICLAZIDE ET DU GLIBENCLAMIDE SUR LES FONCTIONS PLAQUETTAIRES, LA FIBRINOLYSE ET L'EQUILIBRE GLYCEMIQUE CHEZ DES DIABETIQUES PRESENTANT UNE RETINOPATHIE

TitleEffects of gliclazide and glibenclamide on platetet function, fibrinolysis and metabolic control in diabetic patients with retinopathy | EFFETS DU GLICLAZIDE ET DU GLIBENCLAMIDE SUR LES FONCTIONS PLAQUETTAIRES, LA FIBRINOLYSE ET L'EQUILIBRE GLYCEMIQUE CHEZ DES DIABETIQUES PRESENTANT UNE RETINOPATHIE
Authors
Issue Date1982
Citation
Semaine Des Hopitaux, 1982, v. 58 n. 19, p. 1197-1200 How to Cite?
AbstractIn order to compare the metabolic and hemobiological properties of two sulfonylureas, thirty-five non-insulin-dependent diabetics were randomly assigned to two groups. Each group was given either gliclazide (n = 20) or glibenclamide (n = 15) for six months. Metabolic control was improved in both groups, as evidenced by the decrease in HbA1 concentrations. A significant fall in ADP (1 and 4 μM) induced platelet aggregation was recorded in the gliclazide group, while antithrombin III levels remained normal throughout the trial and plasminogen activator levels increased. These hemobiologic changes may be effective in preventing the vascular complications of diabetes. In contrast, glibenclamide did not alter platelet aggregation. Furthermore a significant decrease in both antithrombin III levels and basal and venostasis-stimulated plasminogen activator levels were seen in glibenclamide patients. The beneficial changes in hemostasis seen in gliclazide patients probably result from a direct effect of the drug since hemobiological parameters and metabolic control parameters were not correlated.
Persistent Identifierhttp://hdl.handle.net/10722/161666
ISSN
1999 Impact Factor: 0.069
2002 SCImago Journal Rankings: 0.132
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChan, TKen_US
dc.contributor.authorChan, Ven_US
dc.contributor.authorTeng, CSen_US
dc.contributor.authorYeung, RTTen_US
dc.date.accessioned2012-09-05T05:13:41Z-
dc.date.available2012-09-05T05:13:41Z-
dc.date.issued1982en_US
dc.identifier.citationSemaine Des Hopitaux, 1982, v. 58 n. 19, p. 1197-1200en_US
dc.identifier.issn0037-1777en_US
dc.identifier.urihttp://hdl.handle.net/10722/161666-
dc.description.abstractIn order to compare the metabolic and hemobiological properties of two sulfonylureas, thirty-five non-insulin-dependent diabetics were randomly assigned to two groups. Each group was given either gliclazide (n = 20) or glibenclamide (n = 15) for six months. Metabolic control was improved in both groups, as evidenced by the decrease in HbA1 concentrations. A significant fall in ADP (1 and 4 μM) induced platelet aggregation was recorded in the gliclazide group, while antithrombin III levels remained normal throughout the trial and plasminogen activator levels increased. These hemobiologic changes may be effective in preventing the vascular complications of diabetes. In contrast, glibenclamide did not alter platelet aggregation. Furthermore a significant decrease in both antithrombin III levels and basal and venostasis-stimulated plasminogen activator levels were seen in glibenclamide patients. The beneficial changes in hemostasis seen in gliclazide patients probably result from a direct effect of the drug since hemobiological parameters and metabolic control parameters were not correlated.en_US
dc.languageengen_US
dc.relation.ispartofSemaine des Hopitauxen_US
dc.subject.meshBlood Glucose - Metabolismen_US
dc.subject.meshDiabetic Retinopathy - Blood - Drug Therapyen_US
dc.subject.meshFibrinolysis - Drug Effectsen_US
dc.subject.meshGliclazide - Pharmacology - Therapeutic Useen_US
dc.subject.meshGlyburide - Pharmacology - Therapeutic Useen_US
dc.subject.meshHemoglobin A, Glycosylated - Metabolismen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPlatelet Aggregation - Drug Effectsen_US
dc.subject.meshSulfonylurea Compounds - Pharmacologyen_US
dc.titleEffects of gliclazide and glibenclamide on platetet function, fibrinolysis and metabolic control in diabetic patients with retinopathy | EFFETS DU GLICLAZIDE ET DU GLIBENCLAMIDE SUR LES FONCTIONS PLAQUETTAIRES, LA FIBRINOLYSE ET L'EQUILIBRE GLYCEMIQUE CHEZ DES DIABETIQUES PRESENTANT UNE RETINOPATHIEen_US
dc.typeArticleen_US
dc.identifier.emailChan, V:vnychana@hkucc.hku.hken_US
dc.identifier.authorityChan, V=rp00320en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid6285503-
dc.identifier.scopuseid_2-s2.0-0020326351en_US
dc.identifier.volume58en_US
dc.identifier.issue19en_US
dc.identifier.spage1197en_US
dc.identifier.epage1200en_US
dc.identifier.isiWOS:A1982NP86500010-
dc.identifier.scopusauthoridChan, TK=7402687762en_US
dc.identifier.scopusauthoridChan, V=7202654865en_US
dc.identifier.scopusauthoridTeng, CS=24524091700en_US
dc.identifier.scopusauthoridYeung, RTT=7102833337en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats